Merck releases statement on FDA’s Advisory Committee meeting about suvorexant
Merck, known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration about suvorexant, Merck's investigational medicine to treat insomnia.